As pie in the sky as that sounds spring....given the potential and the valuation assigned to other development stage biotech, I don't think its out to lunch. Maybe not tomorrow, although I certainly wouldn't complain....and no doubt I'd be taking profits.

I think a market cap of between 1-2 billion USD is perfectly justifiable based on the prospects here alone.....yeah that's a wide parameter, but if they realize just half of the apparent potential here then I'd put it north of 10 billion.